2026-01-29
What’s the current state of advanced cell & gene therapies in Sweden? Learn more in the latest episode of Rådet från NT-Rådet Podcast.
Advanced therapies based on cells, genes, or engineered tissues are at the frontier of medicine. These treatments, known collectively as cell & gene therapy or ATMPs (Advanced Therapy Medicinal Products), aim to go beyond symptom management. In some cases, they offer the potential to cure diseases that traditional medicines cannot touch.
In the latest episode of the Rådet från NT-Rådet podcast, leading experts explore what’s happening right now in the field and what it means for patients and healthcare systems.
The podcast episode features in-depth discussion with experts on how authorities handle ATMPs:
Åsa Derolf – Consultant and former chair of NT-rådet
Ricard Nergårdh – Consultant and member of NT-rådet
Maria Lüttgen – Physician and clinical assessor at the Swedish Medical Products Agency, representing Sweden in EMA’s Committee for Advanced Therapies (CAT)
They tackle key questions such as:
What evidence is needed for ATMP approval?
How does EMA balance rare disease challenges with scientific rigor?
What role does NT-rådet play in advising Swedish healthcare?
🎧 Listen to the full episode here:
https://poddtoppen.se/podcast/1460254565/radet-fran-nt-radet/nt-radet-hur-ar-laget-inom-cell-och-genterapi